GeoVax Labs Inc Total Assets
GeoVax Labs Inc total assets. Based on the latest financial reports, GeoVax Labs Inc (GOVX) holds total assets worth $6.73 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see GOVX market cap for the company's overall valuation and market capitalisation.
Total Assets of GeoVax Labs Inc (1996–2024)
Total assets of GeoVax Labs Inc from 1996 to 2024. This chart illustrates how GeoVax Labs Inc's total assets have evolved over time, based on quarterly financial data. See current stock price of GeoVax Labs Inc for real-time trading data and today's change.
GeoVax Labs Inc - Asset Composition Analysis
GeoVax Labs Inc Total Assets Breakdown (December 2024)
GeoVax Labs Inc total assets breakdown as of December 2024. GeoVax Labs Inc's total assets of $6.73 Million consist of 97.3% current assets and 2.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 67.5% |
| Accounts Receivable | $659.41K | 8.1% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $60.00K | 0.7% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1996–2024)
This chart illustrates how GeoVax Labs Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore GeoVax Labs Inc working capital to net assets to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: GeoVax Labs Inc's current assets represent 97.3% of total assets in 2024, an increase from 96.6% in 1996.
- Cash Position: Cash and equivalents constituted 67.5% of total assets in 2024, up from 11.4% in 1996.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1996.
- Asset Diversification: The largest asset category is accounts receivable at 8.1% of total assets.
GeoVax Labs Inc Competitors by Total Assets
Key competitors of GeoVax Labs Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
GeoVax Labs Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.57 | 4.17 | 12.63 |
| Quick Ratio | 3.57 | 4.17 | 12.63 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $4.69 Million | $8.26 Million | $9.42 Million |
GeoVax Labs Inc - Advanced Valuation Insights
This section examines the relationship between GeoVax Labs Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.84 |
| Latest Market Cap to Assets Ratio | 0.04 |
| Asset Growth Rate (YoY) | -12.1% |
| Total Assets | $8.16 Million |
| Market Capitalization | $364.89K USD |
Valuation Analysis
Below Book Valuation: The market values GeoVax Labs Inc's assets below their book value (0.04x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: GeoVax Labs Inc's assets decreased by 12.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for GeoVax Labs Inc (1996–2024)
The table below shows the annual total assets of GeoVax Labs Inc from 1996 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $8.16 Million | -12.14% |
| 2023-12-31 | $9.28 Million | -70.39% |
| 2022-12-31 | $31.35 Million | +165.73% |
| 2021-12-31 | $11.80 Million | +13.50% |
| 2020-12-31 | $10.39 Million | +2116.77% |
| 2019-12-31 | $468.88K | -26.97% |
| 2018-12-31 | $642.00K | +30.96% |
| 2017-12-31 | $490.24K | -19.66% |
| 2016-12-31 | $610.22K | -54.17% |
| 2015-12-31 | $1.33 Million | -0.12% |
| 2014-12-31 | $1.33 Million | -53.05% |
| 2013-12-31 | $2.84 Million | +92.13% |
| 2012-12-31 | $1.48 Million | -10.16% |
| 2011-12-31 | $1.65 Million | -30.23% |
| 2010-12-31 | $2.36 Million | -45.36% |
| 2009-12-31 | $4.32 Million | +41.21% |
| 2008-12-31 | $3.06 Million | -5.86% |
| 2007-12-31 | $3.25 Million | +35.47% |
| 2006-12-31 | $2.40 Million | +2957.28% |
| 2005-12-31 | $78.38K | +309.07% |
| 2004-12-31 | $19.16K | -88.87% |
| 2003-12-31 | $172.20K | -53.59% |
| 2002-12-31 | $371.03K | -90.53% |
| 2001-12-31 | $3.92 Million | -64.90% |
| 2000-12-31 | $11.16 Million | +230.97% |
| 1999-12-31 | $3.37 Million | -49.82% |
| 1998-12-31 | $6.72 Million | -7.56% |
| 1997-12-31 | $7.27 Million | +113.62% |
| 1996-12-31 | $3.40 Million | -- |
About GeoVax Labs Inc
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. The company is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marb… Read more